Anemia is a major source of morbidity and mortality worldwide. Here we review recent
insights into how red blood cells (RBCs) are produced, the pathogenic mechanisms …

Erythropoiesis is a tightly-regulated and complex process originating in the bone marrow
from a multipotent stem cell and terminating in a mature, enucleated erythrocyte. Altered red …

Recently, gene therapy clinical trials have been successfully applied to
hemoglobinopathies, such as sickle cell disease (SCD) and β-thalassemia. Among the great …

Increasing fetal hemoglobin (HbF) levels in adult red blood cells provides clinical benefit to
patients with sickle cell disease and some forms of β-thalassemia. To identify potentially …

β-Thalassemia and sickle cell disease (SCD) are the world's two most widely disseminated
hereditary hemoglobinopathies. β-Thalassemia originated in the Mediterranean, Middle …

Abstract β-Thalassemia pathology is due not only to loss of β-globin (HBB), but also to
erythrotoxic accumulation and aggregation of the β-globin-binding partner, α-globin …

To enable effective oxygen transport,∼ 200 billion red blood cells (RBCs) need to be
produced every day in the bone marrow through the fine-tuned process of erythropoiesis …

Disorders resulting from mutations in the hemoglobin subunit beta gene (HBB; which
encodes β-globin), mainly sickle cell disease (SCD) and β-thalassemia, become …

Inducing fetal hemoglobin (HbF) in red blood cells can alleviate β-thalassemia and sickle
cell disease. We compared five strategies in CD34+ hematopoietic stem and progenitor …

Extensively revised, comprehensive content from leading global contributors ensures that
Hematology, 8th Edition, remains your# 1 choice for expert guidance in all areas of this …